Literature DB >> 21865378

trans-Repression of protein expression dependent on the Epstein-Barr virus promoter Wp during latency.

David J Hughes1, Carol A Dickerson, Marie S Shaner, Clare E Sample, Jeffery T Sample.   

Abstract

An ordered silencing of Epstein-Barr virus (EBV) latency gene transcription is critical for establishment of persistent infection within B lymphocytes, yet the mechanisms responsible and the role that the virus itself may play are unclear. Here we describe two B-cell superinfection models with which to address these problems. In the first, Burkitt lymphoma (BL) cells that maintain latency I, when superinfected, initially supported transcription from the common EBNA promoters Wp and Cp (latency III) but ultimately transitioned to latency I (Cp/Wp silent), an essential requirement for establishment of EBV latency in vivo. We used this model to test whether the early lytic-cycle gene BHLF1, implicated in silencing of the Cp/Wp locus, is required to establish latency I. Upon superinfection with EBV deleted for the BHLF1 locus, however, we have demonstrated that BHLF1 is not essential for this aspect of EBV latency. In the second model, BL cells that maintain Wp-restricted latency, a variant program in which Cp is silent but Wp remains active, sustained the latency III program of transcription from the superinfecting-virus genomes, failing to transition to latency I. Importantly, there was substantial reduction in Wp-mediated protein expression from endogenous EBV genomes, in the absence of Cp reactivation, that could occur independent of a parallel decrease in mRNA. Thus, our data provide evidence of a novel, potentially posttranscriptional mechanism for trans-repression of Wp-dependent gene expression. We suggest that this may ensure against overexpression of the EBV nuclear antigens (EBNAs) prior to the transcriptional repression of Wp in cis that occurs upon activation of Cp.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865378      PMCID: PMC3194970          DOI: 10.1128/JVI.05158-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  82 in total

1.  Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency.

Authors:  M G Davenport; J S Pagano
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.

Authors:  S A Radkov; M Bain; P J Farrell; M West; M Rowe; M J Allday
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Characterisation of regulatory sequences at the Epstein-Barr virus BamHI W promoter.

Authors:  A Bell; J Skinner; H Kirby; A Rickinson
Journal:  Virology       Date:  1998-12-05       Impact factor: 3.616

4.  B-cell lines immortalized with an Epstein-Barr virus mutant lacking the Cp EBNA2 enhancer are biased toward utilization of the oriP-proximal EBNA gene promoter Wp1.

Authors:  L I Yoo; M Mooney; M T Puglielli; S H Speck
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

Authors:  J Levitskaya; A Sharipo; A Leonchiks; A Ciechanover; M G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

6.  Regulation of EBNA gene transcription in lymphoblastoid cell lines: characterization of sequences downstream of BCR2 (Cp).

Authors:  M T Puglielli; N Desai; S H Speck
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Methylation of the Epstein-Barr virus genome in normal lymphocytes.

Authors:  K D Robertson; R F Ambinder
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

8.  Mapping promoter regions that are hypersensitive to methylation-mediated inhibition of transcription: application of the methylation cassette assay to the Epstein-Barr virus major latency promoter.

Authors:  K D Robertson; R F Ambinder
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

9.  Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma.

Authors:  I K Ruf; P W Rhyne; H Yang; C M Borza; L M Hutt-Fletcher; J L Cleveland; J T Sample
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

10.  Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata.

Authors:  J Komano; M Sugiura; K Takada
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more
  10 in total

1.  Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency.

Authors:  David J Hughes; Elessa M Marendy; Carol A Dickerson; Kristen D Yetming; Clare E Sample; Jeffery T Sample
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Genipin as a novel chemical activator of EBV lytic cycle.

Authors:  Myoungki Son; Minjung Lee; Eunhyun Ryu; Aree Moon; Choon-Sik Jeong; Yong Woo Jung; Gyu Hwan Park; Gi-Ho Sung; Hyosun Cho; Hyojeung Kang
Journal:  J Microbiol       Date:  2015-01-28       Impact factor: 3.422

3.  The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.

Authors:  Kristen D Yetming; Lena N Lupey-Green; Sergei Biryukov; David J Hughes; Elessa M Marendy; Jj L Miranda; Jeffery T Sample
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

Review 4.  Epigenetic regulation of EBV persistence and oncogenesis.

Authors:  Italo Tempera; Paul M Lieberman
Journal:  Semin Cancer Biol       Date:  2014-01-24       Impact factor: 15.707

5.  Quercetin-induced apoptosis prevents EBV infection.

Authors:  Minjung Lee; Myoungki Son; Eunhyun Ryu; Yu Su Shin; Jong Gwang Kim; Byung Woog Kang; Hyosun Cho; Hyojeung Kang
Journal:  Oncotarget       Date:  2015-05-20

6.  Cordycepin is a novel chemical suppressor of Epstein-Barr virus replication.

Authors:  Eunhyun Ryu; Myoungki Son; Minjung Lee; Kanghyo Lee; Jae Youl Cho; Sungchan Cho; Suk Kyeong Lee; You Mie Lee; Hyosun Cho; Gi-Ho Sung; Hyojeung Kang
Journal:  Oncoscience       Date:  2014-12-18

7.  Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells.

Authors:  Qinyan Yin; Mark Sides; Christopher H Parsons; Erik K Flemington; Joseph A Lasky
Journal:  Virol J       Date:  2017-06-21       Impact factor: 4.099

8.  The Epstein Barr virus circRNAome.

Authors:  Nathan Ungerleider; Monica Concha; Zhen Lin; Claire Roberts; Xia Wang; Subing Cao; Melody Baddoo; Walter N Moss; Yi Yu; Michael Seddon; Terri Lehman; Scott Tibbetts; Rolf Renne; Yan Dong; Erik K Flemington
Journal:  PLoS Pathog       Date:  2018-08-06       Impact factor: 6.823

9.  Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.

Authors:  Yuchen Zhang; Chang Jiang; Stephen J Trudeau; Yohei Narita; Bo Zhao; Mingxiang Teng; Rui Guo; Benjamin E Gewurz
Journal:  mBio       Date:  2020-10-27       Impact factor: 7.867

10.  In vitro Studies and Clinical Observations Imply a Synergistic Effect Between Epstein-Barr Virus and Dengue Virus Infection.

Authors:  Xiao-Mei Deng; Ling-Zhai Zhao; Xue-Ying Liang; Dan Li; Lei Yu; Fu-Chun Zhang; Hua Zhang; Zhong-Yu Liu; Pei Xu
Journal:  Front Microbiol       Date:  2021-06-18       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.